OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug
Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile …

Abstract Phosphodiesterase 5 (PDE 5) inhibitors are selective inhibitors of the enzyme PDE
5, which catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP), a potent …

Introduction Several methods have been so far proposed to compare the effectiveness of the
three available phosphodiesterase type 5 inhibitors (PDE5Is). Methods Two urologists (EC …

Introduction Erectile dysfunction (ED) is a very common multidimensional disorder affecting
men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship …

Based on the increasing knowledge on both the physiology of penile erection and the
pathophysiology of erectile dysfunction, selective phosphodiesterase (PDE) inhibitors have …

Three different phosphodiesterase 5 (PDE5) inhibitors are currently available for the
treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. The differences between …

Phosphodiesterase type-5 (PDE-5) is an enzyme that catalyzes the hydrolytic degradation of
cyclic GMP–an essential intracellular second messenger that modulates diverse biological …

Introduction With the success of Phosphodiesterase (PDE) type 5 inhibitors (ie, sildenafil,
tadalafil, vardenafil) in the treatment of erectile dysfunction (ED), PDEs are considered …

The clinical properties (efficacy and safety profile) of a medicine are related not only to its
mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are …

Erectile dysfunction is usually of vascular origin and is frequently encountered in men with
cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has …